Demethylation demystification

Blood

Volumn 121, Issue 9, 2013, Pages 1488-1489

  Suarez, Lauren ^a   Gore, Steven D ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; AZACITIDINE; CYTARABINE; DNA METHYLTRANSFERASE 1; UVOMORULIN;

ACUTE GRANULOCYTIC LEUKEMIA; CELL CYCLE S PHASE; CELL DIVISION; CLINICAL FEATURE; CPG ISLAND; DRUG POTENCY; HUMAN; IN VITRO STUDY; METHYLATION; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHORT SURVEY; SURVIVAL; TREATMENT RESPONSE;

EID: 84876444975     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-02-483735     Document Type: Short Survey

References (10)

1. Taylor SM, Jones PA. Multiple new phenotypes induced in 10T12 and 3T3 cells treated with 5-Azacytidine. Cell. 1979;17(4):771-779. (Pubitemid 9252286)
2. Silverman LR, Holland JF, Weinberg RS, et al. Effects of treatment with 5-Azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia. 1993;7(Suppl 1):21.
3. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223-232.
4. Jones PA, Taylor SM. Hemimethylated duplex DNAs prepared from 5-Azacytidine-Treated cells. Nucleic Acids Res. 1981;9(12):2933-2947.
5. Taylor SM, Jones PA. Mechanism of action of eukaryoticDNAmethyltransferase: Use of 5-Azacytosinecontaining DNA. J Mol Biol. 1982;162(3):679-692. (Pubitemid 13113000)
6. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation.NEngl J Med. 2003;349(21):2042-2054. (Pubitemid 37448928)
7. Daskalakis M, Nguyen TT, Nguyen C, et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2-deoxycytidine (decitabine) treatment. Blood. 2002;100(8):2957-2964.
8. FandyTE,HermanJG,KernsP, et al. Early epigenetic changesandDNAdamagedonot predict clinical response in an overlapping schedule of 5- Azacytidineandentinostat in patients with myeloid malignancies. Blood. 2009;114(13):2764-2773.
9. Klco JM, Spencer DH, Lamprecht TL, et al. Genomic impact of transient low-dose decitabine treatment on primaryAMLcells. Blood. 2013;121(9):1633-1643.
10. Yan P, Frankhouser D, MurphyM,et al. Genome-wide methylation profiling in decitabine-Treated patients with acute myeloid leukemia. Blood. 2012;120(12):2466-2474.